RB1 is one of the major substrates of CDK6 and palbociclib treatment resulted in reduced phosphorylation of RB1 and G1 cell cycle arrest in MM cell lines, consistent with previous studies in cancer42,43. This evidence concerns the gene RB1 and Miyoshi myopathy.